No Data
No Data
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Market Cap Decline of US$89m May Not Have as Much of an Impact on Institutional Owners After a Year of 1.4% Returns
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Institutional Investors Lost 8.6% Over the Past Week but Have Profited From Longer-term Gains
Key Insights Significantly high institutional ownership implies Lyell Immunopharma's stock price is sensitive to their trading actions 52% of the business is held by the top 6 shareholders Using d
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) fell during Monday's session after the company reportedly saw a decline in Fe
Express News | On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY
HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $8 to $6.
Lyell Immunopharma Files $400M Mixed Securities Shelf
No Data